

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

### Single Technology Appraisal

#### Crovalimab for treating paroxysmal nocturnal haemoglobinuria ID6140

#### Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>Roche (crovalimab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Beacon</li> <li>Genetic Alliance UK</li> <li>PNH Support</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>The Aplastic Anaemia Trust</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>Anaemia Nurse Specialist Association</li> <li>British Blood Transfusion Society</li> <li>British Geriatrics Society</li> <li>British Society for Genetic Medicine</li> <li>British Society for Haematology</li> <li>British Society for Immunology</li> <li>NHS Blood and Transplant</li> <li>National PNH Service</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>UK Clinical Pharmacy Association</li> <li>UK Forum on Haemoglobin Disorders</li> <li>United Kingdom National Screening Committee</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>Department of Health and Social Care</li> <li>NHS England</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Hospital Information Services - Jehovah's Witnesses</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>National Services Division</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>Alexion Pharmaceuticals (danicopan, eculizumab, ravulizumab)</li> <li>Novartis (iptacopan)</li> <li>Swedish Orphan Biovitrum (pegcetacoplan)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>Cochrane Haematological Malignancies Group</li> <li>Cochrane UK</li> <li>Genomics England</li> <li>MRC Clinical Trials Unit</li> </ul>

Provisional stakeholder list for the evaluation of crovalimab for treating paroxysmal nocturnal haemoglobinuria ID6140

Issue date: September 2023

© National Institute for Health and Care Excellence 2023. All rights reserved.

Page 1 of 2

Consultees	Commentators (no right to submit or appeal)
	<ul style="list-style-type: none"> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination, and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts, and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

#### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.